-
Transforming Clinical Trials Initiative 2025 Third Quarter Updates
LUNGevity Foundation’s Transforming Clinical Trials Initiative (TCTI) develops collaborative strategies to enhance innovation and patient access to safe and effective lung cancer -
Dose-Finding and US Representativeness under the Spotlight at the ODAC’s July 2025 Meeting
The US Food and Drug Administration (FDA) Oncologic Drug Advisory Committee (ODAC) met on July 17th, 2025 to review the results of clinical trials DREAMM-7 and DREAMM-8 assessing -
How the May 2025 ODAC Meeting Could Still Impact Future Lung Cancer Clinical Trials
The US Food and Drug Administration (FDA) Oncologic Drug Advisory Committee (ODAC) convened on May 20th and 21st to weigh in on four different regimens across a variety of cancer